Literature DB >> 10996626

Cytokines in cancer therapy.

G Parmiani1, L Rivoltini, G Andreola, M Carrabba.   

Abstract

Cytokines are crucial factors in the activation and development of immune response, including responses against tumor cells. Interleukin (IL)-2, a T-cell growth factor, has been largely used to activate T and NK cells in vivo and to maintain such an activation for therapeutic purposes. When given to patients, IL-2 was shown to cause clinical responses, especially in metastatic melanoma and renal cancer patients, though its mechanism of action could not be completely elucidated. Cytokines (IL-2, IL-12, GM-CSF) are also used as natural adjuvants of vaccines of various formulation to help in activating and maintaining an antitumor immune response. This review summarizes findings deriving from the use of cytokines in cancer therapy and provides insights into future approaches when a more appropriate use of cytokines, together with new vaccines, is likely to improve clinical outcome.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10996626     DOI: 10.1016/s0165-2478(00)00247-9

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  15 in total

1.  IL-2 regulates the expression of the tumor suppressor IL-24 in melanoma cells.

Authors:  Emily Y Jen; Nancy J Poindexter; Elizabeth S Farnsworth; Elizabeth A Grimm
Journal:  Melanoma Res       Date:  2012-02       Impact factor: 3.599

Review 2.  Antibody-cytokine fusion proteins: applications in cancer therapy.

Authors:  Elizabeth Ortiz-Sánchez; Gustavo Helguera; Tracy R Daniels; Manuel L Penichet
Journal:  Expert Opin Biol Ther       Date:  2008-05       Impact factor: 4.388

Review 3.  Chemokines, costimulatory molecules and fusion proteins for the immunotherapy of solid tumors.

Authors:  Melissa G Lechner; Sarah M Russell; Rikki S Bass; Alan L Epstein
Journal:  Immunotherapy       Date:  2011-11       Impact factor: 4.196

4.  An engineered 4-1BBL fusion protein with "activity on demand".

Authors:  Jacqueline Mock; Marco Stringhini; Alessandra Villa; Michael Weller; Tobias Weiss; Dario Neri
Journal:  Proc Natl Acad Sci U S A       Date:  2020-11-25       Impact factor: 11.205

5.  CD40 stimulation accelerates deletion of tumor-specific CD8(+) T cells in the absence of tumor-antigen vaccination.

Authors:  R M Kedl; M Jordan; T Potter; J Kappler; P Marrack; S Dow
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-28       Impact factor: 11.205

6.  Curcumin reverses T cell-mediated adaptive immune dysfunctions in tumor-bearing hosts.

Authors:  Sankar Bhattacharyya; Dewan Md Sakib Hossain; Suchismita Mohanty; Gouri Sankar Sen; Sreya Chattopadhyay; Shuvomoy Banerjee; Juni Chakraborty; Kaushik Das; Diptendra Sarkar; Tanya Das; Gaurisankar Sa
Journal:  Cell Mol Immunol       Date:  2010-03-22       Impact factor: 11.530

Review 7.  Bacterial therapies: completing the cancer treatment toolbox.

Authors:  Adam T St Jean; Miaomin Zhang; Neil S Forbes
Journal:  Curr Opin Biotechnol       Date:  2008-09-18       Impact factor: 9.740

8.  Osmotic-driven release kinetics of bioactive therapeutic proteins from a biodegradable elastomer are linear, constant, similar, and adjustable.

Authors:  Frank Gu; Ronald Neufeld; Brian Amsden
Journal:  Pharm Res       Date:  2006-03-24       Impact factor: 4.200

Review 9.  Immunotherapy of autoimmunity and cancer: the penalty for success.

Authors:  Rachel R Caspi
Journal:  Nat Rev Immunol       Date:  2008-12       Impact factor: 53.106

Review 10.  Genetically engineered mesenchymal stem cells: targeted delivery of immunomodulatory agents for tumor eradication.

Authors:  Meysam Mosallaei; Miganoosh Simonian; Naeim Ehtesham; Mohammad Reza Karimzadeh; Nasim Vatandoost; Babak Negahdari; Rasoul Salehi
Journal:  Cancer Gene Ther       Date:  2020-05-18       Impact factor: 5.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.